AbbVie announced this morning it would buy clinical-stage biotech company Capstan Therapeutics for up to $2.1 billion in cash, picking up the company's in vivo CAR-T therapy candidate. San Diego-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback